Clinicopathologic Characteristics of 342 Patients With Multicentric Castleman Disease in Japan

Modern Rheumatology - United Kingdom
doi 10.1080/14397595.2019.1704983
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

FDA Approval: Siltuximab for the Treatment of Patients With Multicentric Castleman Disease

Clinical Cancer Research
Cancer ResearchOncology
2015English

Multicentric Castleman Disease: An Unusual Breast Lump

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Biologic Agents in the Treatment of Multicentric Castleman Disease

Turkish Thoracic Journal
PulmonaryRespiratory Medicine
2018English

Siltuximab: A Targeted Therapy for Idiopathic Multicentric Castleman Disease

Immunotherapy
OncologyAllergyImmunology
2016English

Long-Term Safety of Siltuximab in Patients With Idiopathic Multicentric Castleman Disease: A Prespecified, Open-Label, Extension Analysis of Two Trials

The Lancet Haematology
Hematology
2020English

Complete Remission in a Patient With Human Herpes Virus-8 Negative Multicentric Castleman Disease Using CHOP Chemotherapy

Cancer Research and Treatment
Cancer ResearchOncology
2009English

Clinicopathologic Characteristics and Prognosis of Patients With Adrenocortical Carcinoma

Japanese Journal of Urology
Urology
2014English

Outcome and Late Complications of Radiotherapy in Patients With Unicentric Castleman Disease

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2006English

Efficacy of Bortezomib in Refractory Form of Multicentric Castleman Disease Associated to Poems Syndrome (MCD-POEMS Variant)

Annals of Hematology
MedicineHematology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy